Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hyperhomocysteinemia. A new coronary risk factor].

R Zacarías-Castillo1, A E Hernández-Rebollar, A Zajarias-Rabchinskey

  • 1Departamento de Medicina Interna, Hospital General Dr. Manuel Gea González, Calzada de Tlalpan 4800, CP 14000, México, DF. rzac99@hotmail.com

Gaceta Medica De Mexico
|August 25, 2001
PubMed
Summary

High homocysteine levels contribute to atherosclerosis, a major cause of death. Folic acid and B vitamins can lower homocysteine, aiding in preventing and treating vascular disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Obesity and metabolic syndrome as public health problem. A reflection].

Archivos de cardiologia de Mexico·2008
Same author

[Role of tumor necrosis factor alpha in atherosclerosis].

Archivos de cardiologia de Mexico·2001
Same author

[Otoneurologic abnormalities in insulin-dependent diabetes].

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion·1998
Same author

Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix.

Human reproduction (Oxford, England)·1997
Same author

Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord.

Urology·1995
Same author

Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75).

European journal of endocrinology·1994

Area of Science:

  • Cardiovascular Medicine
  • Nutritional Biochemistry

Context:

  • Cardiovascular disease is the primary cause of mortality in Mexico and Western nations.
  • Traditional atherosclerosis risk factors inadequately explain its prevalence.
  • Hyperhomocysteinemia is an emerging risk factor for atherosclerosis.

Purpose:

  • To explore the role of hyperhomocysteinemia in atherosclerosis.
  • To investigate the impact of homocysteine on vascular health.
  • To assess the potential of nutrient supplements in managing homocysteine levels.

Summary:

  • Elevated homocysteine, an amino acid from protein metabolism, promotes endothelial damage and oxidative stress, contributing to atherosclerosis.
  • Plasma homocysteine levels above 15 mmol/L, or lower with other risk factors, accelerate atherosclerotic development.

Related Experiment Videos

  • Folic acid and vitamins B6 and B12 effectively reduce homocysteine levels.

    • Impact:

    • Hyperhomocysteinemia is a significant, underrecognized contributor to atherosclerotic vascular disease.
    • Nutritional interventions targeting homocysteine may offer a novel strategy for cardiovascular disease prevention and treatment.